key: cord-0808555-95l9ws2c
authors: Chiuppesi, Flavia; Nguyen, Vu H.; Park, Yoonsuh; Contreras, Heidi; Karpinski, Veronica; Faircloth, Katelyn; Nguyen, Jenny; Kha, Mindy; Johnson, Daisy; Martinez, Joy; Iniguez, Angelina; Zhou, Qiao; Kaltcheva, Teodora; Frankel, Paul; Kar, Swagata; Sharma, Ankur; Andersen, Hanne; Lewis, Mark G.; Shostak, Yuriy; Wussow, Felix; Diamond, Don J.
title: Synthetic Multiantigen MVA Vaccine COH04S1 Protects Against SARS-CoV-2 in Syrian Hamsters and Non-Human Primates
date: 2021-09-15
journal: bioRxiv
DOI: 10.1101/2021.09.15.460487
sha: aaf480179550e599e10c828cde1af28b8ac106d2
doc_id: 808555
cord_uid: 95l9ws2c

Second-generation COVID-19 vaccines could contribute to establish protective immunity against SARS-CoV-2 and its emerging variants. We developed COH04S1, a synthetic multiantigen Modified Vaccinia Ankara-based SARS-CoV-2 vaccine that co-expresses spike and nucleocapsid antigens. Here, we report COH04S1 vaccine efficacy in animal models. We demonstrate that intramuscular or intranasal vaccination of Syrian hamsters with COH04S1 induces robust Th1-biased antigen-specific humoral immunity and cross-neutralizing antibodies (NAb) and protects against weight loss, lower respiratory tract infection, and lung injury following intranasal SARS-CoV-2 challenge. Moreover, we demonstrate that single-dose or two-dose vaccination of non-human primates with COH04S1 induces robust antigen-specific binding antibodies, NAb, and Th1-biased T cells, protects against both upper and lower respiratory tract infection following intranasal/intratracheal SARS-CoV-2 challenge, and triggers potent post-challenge anamnestic antiviral responses. These results demonstrate COH04S1-mediated vaccine protection in animal models through different vaccination routes and dose regimens, complementing ongoing investigation of this multiantigen SARS-CoV-2 vaccine in clinical trials.

Since the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in China 30 at the end of 2019, SARS-CoV-2 has spread rapidly worldwide, causing a global pandemic with 31 millions of fatalities 1,2 . Several SARS-CoV-2 vaccines were developed in response to the COVID-32 19 pandemic with unprecedented pace and showed 62-95% efficacy in Phase 3 clinical trials, 33 leading to their emergency use authorization (EUA) in many countries by the end of 34 2020/beginning of 2021 3-8 . This includes vaccines based on mRNA, adenovirus vectors, and 35 nanoparticles that utilize different antigenic forms of the spike (S) protein to induce protective 36 immunity against SARS-CoV-2 primarily through the function of neutralizing antibodies (NAb) 9-12 . 37

While the Phase 3 efficacy results provide hope for a rapid end of the COVID-19 pandemic, 38

waning antibody responses and evasion of NAb by emerging variants of concern (VOC) pose 39 imminent challenges for durable vaccine protection and herd immunity [13] [14] [15] [16] [17] [18] [19] . Alternative vaccines 40 based on different platforms or modified epitope or antigen design could therefore contribute to 41 establish long-term and cross-reactive immunity against SARS-CoV-2 and its emerging VOC. 42

While NAb blocking S-mediated entry are considered the principal SARS-CoV-2 immune correlate 43 of protection, humoral and cellular immune responses to multiple antigens have been implicated 44 in the protection against SARS-CoV-2 10,11,20 . Besides the S protein, the nucleocapsid (N) protein 45 is well-recognized as a dominant target of antibody and T cell responses in SARS-CoV-2-infected 46 individuals and therefore suggested as an additional immunogen to augment vaccine-mediated 47 protective immunity 21-24 . Its high conservation and universal cytoplasmic expression makes the N 48 protein an attractive complementary target antigen to elicit durable and broadly reactive T cells 23 . 49

Several recent studies highlight the benefits of N as a vaccine antigen in animal models [25] [26] [27] [28] . 50

We previously constructed multiantigenic SARS-CoV-2 vaccine candidates using a fully synthetic 51 platform based on the well-characterized and clinically proven Modified Vaccinia Ankara (MVA) 52 vector 29-32 , which is marketed in the USA as Jynneos™ (Bavarian-Nordic) 33 . MVA is a highly 53 attenuated poxvirus vector that is widely used to develop vaccines for infectious diseases and 54 cancer due to its excellent safety profile in animals and humans, versatile delivery and expression 55 system, and ability to stimulate potent humoral and cellular immune responses to heterologous 56 antigens 30-32 . We have used MVA to develop vaccine candidates for preclinical testing in animal 57 models of congenital cytomegalovirus disease while demonstrating vaccine efficacy in several 58 clinical trials in solid tumor and stem cell transplant patients [34] [35] [36] [37] [38] [39] . Using the synthetic MVA (sMVA) 59 platform, we constructed sMVA vectors co-expressing full-length S and N antigen sequences that 60 showed potent immunogenicity in mice to stimulate SARS-CoV-2 antigen-specific humoral and 61 cellular immune responses, including high-titer NAb 29 . One of these sMVA constructs forms the 62 basis of clinical vaccine candidate COH04S1, which has shown to be safe and immunogenic in a 63 randomized, double-blinded, placebo-controlled, single center Phase 1 trial in healthy adults 64 (NCT04639466), and is currently evaluated in a randomized, double-blinded, single center Phase 65 2 trial in hematology patients who have received cellular therapy (NCT04977024). 66

In this report, we demonstrate that COH04S1 stimulates protective immunity against SARS-CoV-67 respiratory tract infection by COH04S1 independent of the vaccination route (Fig. S2) . 132

Histopathological findings in hematoxylin/eosin-stained lung sections of euthanized animals were 133 assessed by a board-certified pathologist and scored in a blinded manner on a scale from 1 to 5 134 based on the severity and diffusion of the lesions (Table S2) showed a mild form of bronchioalveolar hyperplasia and grade 1 interstitial inflammation in a 143 subset of animals, indicating that IN vaccination with COH04S1 mediated potent but incomplete 144 vaccine protection against SARS-CoV-2-mediated lung damage in this model ( Fig. 2e-h) . 145

Correlative analysis of pre-challenge immunity and post-challenge outcome revealed that any of 146 the evaluated COH04S1-induced responses, including S, RBD, and N-specific antibodies and 147

NAb, correlated with protection from weight loss, lung infection, and lung pathology (Fig. S3) , 148

confirming that the observed protection was vaccine-mediated. These results in sum demonstrate 149 that hamsters vaccinated IM and IN with COH04S1 are protected from progressive weight loss, 150 lower respiratory tract infection, and severe lung pathology following SARS-CoV-2 challenge. 151 2D and 1D vaccination of NHP with COH04S1 stimulates robust antigen-specific binding 152 antibodies, NAb responses, and antigen-specific IFN and IL-2 expressing T cells 153 NHP represent a mild COVID-19 disease model that is widely used to bolster preclinical SARS-154

CoV-2 vaccine efficacy against upper and lower respiratory tract infection in an animal species 155 that is more closely related to humans 49-56 . We used the African green monkey NHP model to 156 assess COH04S1 vaccine protection against SARS-CoV-2 by 2D and 1D vaccination regimens, 157 referred to as COH04S1-2D and COH04S1-1D, respectively. For 2D vaccination, NHP were 158 vaccinated twice in a four week interval with 2.5x10 8 PFU of COH04S1. For 1D vaccination, NHP 159 were vaccinated once with 5x10 8 PFU of COH04S1 (Fig. 3a) . As controls, NHP were either mock-160 vaccinated or vaccinated with empty sMVA vector via the same schedule and dose vaccination 161 regimen. Robust serum binding antibodies to S, RBD, and N were stimulated in NHP by both 162 COH04S1-2D and COH04S1-1D, whereas binding antibodies in the 2D vaccine group were 163 strongly boosted after the second dose. At the time of challenge, S-and RBD-specific antibody 164 titers measured in the 2D and 1D vaccine groups were comparable ( Fig. 3b-d, and S4 ), while N-165 specific titers appeared higher in the 2D vaccine group than in the 1D vaccine group. Notably, 166 similar S-specific antibody titers were measured in 2D-and 1D-vaccinated NHP by S antigens 167 based on the original Wuhan-Hu-1 reference strain and various VOC (Beta, Gamma, Delta), 168

whereas binding antibodies measured with the VOC-specific S antigens tended to be lower than 169

those measured with the Wuhan-Hu-1 S antigen (Figs. 3e, and S4). Antigen-specific binding 170 antibodies were also measured in lung bronchioalveolar lavage (BAL) samples two weeks pre-171 challenge. BAL IgG binding antibodies to S, RBD, and N were detected in both COH04S1-2D and 172 COH04S1-1D-vaccinated NHP, although BAL IgG antibody titers measured at this time point pre-173 challenge were higher in the 2D vaccine group than in the 1D vaccine group (Figs. 3f, and S4) . At two weeks pre-challenge, we also assessed SARS-CoV-2-specific T cells in COH04S1-182 vaccinated NHP. Both 2D and 1D vaccination with COH04S1 stimulated robust IFN and IL-2-183 expressing S and N antigen-specific T cells, whereas no or only very low levels of IL-4-expressing 184 S and N-specific T cells were observed in COH04S1-2D-or COH04S1-1D-vaccinated animals, 185 consistent with Th1-biased immunity (Figs. 3h-i, and S5). S-specific T cells were generally 186 detected at a higher frequency than N-specific T cells in both the COH04S1-2D and COH04S1-187 1D vaccine groups. In addition, S-specific T cells measured at this time point pre-challenge were 188 detected at a higher frequency in 2D-vaccinated NHP than in 1D-vaccinated NHP. These results 189 demonstrate that COH04S1 elicits robust antigen-specific binding antibodies, NAb, and antigen-190 specific IFN and IL-2-expressing T cells in NHP through 2D and 1D vaccination regimens. between COH04S1 vaccine and control groups, and no increase in inflammation was observed 230 for COH04S1-vaccinated NHP compared to control animals (Table S3) These results in sum demonstrate that COH04S1 has the capacity to elicit potent and cross-367 reactive Th1-biased S and N-specific humoral and cellular responses that protect hamsters and 368 NHP from SARS-CoV-2 by different vaccination routes and dose regimens. This multi-antigen 369 sMVA-vectored SARS-CoV-2 vaccine could be complementary to available vaccines to induce 370 robust and long-lasting protective immunity against SARS-CoV-2 and its emerging VOC. 371

Methods 372

COH04S1 is a double-plaque purified virus isolate derived from the previously described sMVA-374 N/S vector (NCBI Accession# MW036243), which was generated using the three-plasmid system 375 of the sMVA platform and fowlpox virus TROVAC as a helper virus for virus reconstitution 29 . 376 COH04S1 co-expresses full-length S and N antigen sequences based on the Wuhan-Hu-1 377 reference strain (NCBI Accession# NC_045512) 29 . Sequence identity of COH04S1 seed stock 378 virus was assessed by PaqBio long-read sequencing. COH04S1 and sMVA vaccine stocks for 379 animal studies were produced using chicken embryo fibroblasts (CEF) and prepared by 36% 380 sucrose cushion ultracentrifugation and virus resuspension in 1 mM Tris-HCl (pH 9). Virus stocks 381

were stored at −80°C and titrated on CEF by plaque immunostaining as described 29 . Viral stocks 382

were validated for antigen insertion and expression by PCR, sequencing, and Immunoblot. 383

In life portion of hamsters and NHP studies were carried out at Bioqual Inc. (Rockville, MD). Thirty The reaction was stopped with 1M H2SO4 and plates were immediately read on FilterMax F3 420 (Molecular Devices). For binding antibody detection in NHP serum, a similar protocol was used. 421

Wash buffer was 0.1% Tween-20 in PBS, and blocking buffer was 1% casein/PBS for RBD and 422 N antigen ELISA and 4% Normal Goat Serum/1% casein/PBS for S ELISA. For IgG quantification 423 in NHP BAL samples 1% BSA/PBS was used as blocking and sample buffers. Goat anti-Monkey 424 IgG (H+L) secondary antibody (ThermoFisher PA1-84631) was diluted 1:10,000. Endpoint titers 425

were calculated as the highest dilution to have an absorbance >0.100. 426

NAb were measured by PRNT assay using SARS-CoV-2 USA-WA1/2020 strain (Lot # 080420-428 900). The stock was generated using Vero-E6 cells infected with seed stock virus obtained from 429 

SARS-CoV-2 PV was produced using a plasmid lentiviral system based on pALD-gag-pol, pALD-443 rev, and pALD-GFP (Aldevron). Plasmid pALD-GFP was modified to express Firefly luciferase 444 (pALD-Fluc). Plasmid pCMV3-S (Sino Biological VG40589-UT) was used and modified to express 445 SARS-CoV-2 Wuhan-Hu-1 S with D614G modification. Customized gene sequences cloned into 446 pTwist-CMV-BetaGlobin (Twist Biosciences) were used to express SARS-CoV-2 VOC-specific S 447 variants (Table S1 ). All S antigen were expressed with C-terminal 19aa deletion. A transfection 448 mixture was prepared 1ml OptiMEM that contained 30 µl of TransIT-Lenti transfection reagent 449 (Mirus MIR6600) and 6 µg pALD-Fluc, 6 µg pALD-gag-pol, 2.4 µg pALD-rev, and 6.6 µg S 450 expression plasmid. The mixture was added to 5x10 6 HEK293T/17 cells (ATCC CRL11268) 451 seeded the day before in 10 cm dishes and the cells were incubated for 72h at 37°C. Supernatant The neutralization titer for each dilution was calculated as follows: NT = [1−(mean luminescence 465 with immune sera/mean luminescence without immune sera)] × 100. The titers that gave 50% 466 neutralization (NT50) were calculated by determining the linear slope of the graph plotting NT 467 versus serum dilution by using the next higher and lower NT using Office Excel (v2019). 468

Peripheral blood mononuclear cells (PBMC) were isolated from fresh blood using Ficoll and 470 counted using Luna-FL cell counter (Logos Biosystems). Pre-immune samples were evaluated 471

using Human IFN-γ/IL-4 Double-Color FluoroSpot (ImmunoSpot); however, this kit only allowed 472 to assess NHP IFN-γ but not NHP IL-4. The remaining time-points were evaluated using Monkey using primer/probe sequences that were specifically designed to amplify and bind to a region of 516 the N gene mRNA that is not packaged into virions. SARS-CoV-2 RNA was extracted from 517 samples as described above. The signal was compared to a known standard curve of plasmid 518 containing a cDNA copy of the N gene mRNA target region to give copies per ml. For amplification, 519 the plate was placed in an Applied Biosystems 7500 Sequence detector and amplified using the 520 following program: 48°C for 30 minutes, 95°C for 10 minutes followed by 40 cycles of 95°C for 15 521 seconds, and 1 minute at 55°C. The number of copies of RNA per ml was calculated by 522 extrapolation from the standard curve and multiplying by the reciprocal of 0.2 ml extraction 523

volume. This gave a practical range of 50 to 5 x 10 7 RNA copies per swab or ml BAL fluid. analysis. Tissues were processed through to paraffin blocks, sectioned once at approximately 5 537 microns thickness, and stained with hematoxylin/eosin. Board certified pathologists were blinded 538 to the vaccine groups and mock controls were used as a comparator. 539

Statistical analyses were performed using Prism 8 (GraphPad, v8.3.0). One-way ANOVA with 541

Holm-Sidak's multiple comparison test, two-way ANOVA with Tukey's or Dunn's multiple 542 comparison test, Kruskal-Wallis test followed by Dunn's multiple comparison test, and Spearman 543 correlation analysis were used. All tests were two-sided. The test applied for each analysis and 544 the significance level is indicated in each figure legend. Prism 8 was used to derive correlation 545 matrices. 546 values + geometric SD. Dotted lines indicate lower limit of detection. Two-way ANOVA with 757

Tukey's multiple comparison test was used. e. IgG2-3/IgG1 ratios. S, RBD, and N antigen-758 specific IgG2-3 and IgG1 endpoint titers were measured at day 42 (d42) in serum samples of 759 vaccine and control groups and used to assess IgG2-3/IgG1 ratios. An IgG2-3/IgG1 ratio >1 is 760

indicative of a Th1-biased response. Geometric means are indicated with a line. f-g. NAb titers.

NAb titers were measured in serum samples of vaccine and control groups post-first (d28) and 762

post-second (d42) immunization via PRNT assay against SARS-CoV-2 infectious virus. Data are 763 respectively. Dotted line represents the maximum weight loss allowed before euthanasia. Peaks 781 of weight loss in each group were compared using one-way ANOVA followed by Tukey's multiple 782 comparison test. c-d. Lung viral loads. SARS-CoV-2 genomic RNA (gRNA) and sub-genomic 783 RNA (sgRNA) copies were quantified in lung tissue of vaccine and control groups at day 10 post-784 challenge by qPCR. Bars show RNA copies geometric mean ± geometric SD. Dotted lines 785 represent lower limit of detection. Kruskal-Wallis test followed by Dunn's multiple comparison test 786 was used. e-h. Histopathological findings. Hematoxylin/eosin-stained lung sections of 787 COH04S1-vaccinated hamsters and control animals at day 10 post challenge were evaluated by 788 a board-certified pathologist and microscopic findings were graded based on severity on a scale 789 from 1 to 5 (Table S2) . Panel e shows the cumulative pathology score of all histopathologic 790 findings in each group. Panel f shows grading of bronchioalveolar hyperplasia disease severity in 791 each group. One-way ANOVA followed by Holm-Sidak's multiple comparison test was used. 792

Panel g shows the severity of lung inflammatory microscopic findings based on 1-to-5 scaling of 793 four inflammation types as indicated. Bars in e-g represent mean values ±SD. One-way ANOVA 794 sMVA vector control animals. Bars represent geometric means, lines represent ±geometric SD. 838

Dotted lines represent lower limit of detection. Two-way ANOVA followed by Sidak's multiple 839 comparison test was used. Panels c ,f, and i show viral loads by area under the curve (AUC). 840

Violin plots show values ranges with median values (dashed line) and quartiles (dotted line).

AUC=0 was indicated as 1. One-way ANOVA followed by Tukey's multiple comparison test was 842

used. *=0.05 < p <0.01, **=0.01 < p < 0.001, ***=0.001 < p < 0.0001, ****=p < 0.0001. 843 as 1. One-way ANOVA followed by Tukey's multiple comparison test was used. *=0.05 < p <0.01, 853 **=0.01 < p < 0.001, ***=0.001 < p < 0.0001, ****=p < 0.0001. 854 855 threshold of 30 spots/10 6 cells. Two-way ANOVA followed by Tukey's multiple comparison test 867

A pneumonia outbreak associated with a new coronavirus of probable bat origin

A Novel Coronavirus from Patients with Pneumonia in China

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222)

CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the 557 UK

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-559 boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

SARS-CoV-2 vaccines in development

The receptor binding domain of the viral spike protein is an 566 immunodominant and highly specific target of antibodies in SARS-CoV-2 patients

Correlates of protection against SARS-CoV-2 in rhesus macaques

Correlates of protection from SARS-CoV-2 infection

Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine

Detection of a SARS-CoV-2 variant of concern in South Africa

Multiple SARS-CoV-2 variants escape neutralization by vaccine-577 induced humoral immunity

Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-579 induced sera

Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus

Antibody evasion by the P.1 strain of SARS-CoV-2

SARS-CoV-2 Vaccines and the Growing Threat of Viral Variants

Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 587 Variant

Not just antibodies: B cells and T cells mediate immunity to COVID-589 19

Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-591 19 Disease and Unexposed Individuals

Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity

The Nucleocapsid Protein of SARS-CoV-2: a Target for 596 Vaccine Development

Broad and strong memory CD4(+) and CD8(+) T cells induced by SARS-CoV-2 in UK 598 convalescent individuals following COVID-19

A Synthetic Peptide CTL Vaccine Targeting Nucleocapsid Confers Protection 601 from SARS-CoV-2 Challenge in Rhesus Macaques. Vaccines (Basel)

Combining spike-and 604 nucleocapsid-based vaccines improves distal control of SARS-CoV-2

Immunization with RBD-P2 and N protects against SARS-CoV-2 in nonhuman 607 primates

Nucleocapsid Vaccine Elicits Spike-Independent SARS-CoV-2 Protective 609 Immunity

Development of a multi-antigenic SARS-CoV-2 vaccine candidate using a 611 synthetic poxvirus platform

Clinical development of Modified Vaccinia virus Ankara vaccines

Nonreplicating vaccinia vector efficiently expresses recombinant genes

Modified Vaccinia Virus Ankara: History, Value in Basic Research, and 617 Current Perspectives for Vaccine Development

Phase 3 Efficacy Trial of Modified Vaccinia Ankara as a Vaccine against 620 Smallpox

Human cytomegalovirus vaccine based on the envelope gH/gL pentamer 622 complex

A vaccine based on the rhesus cytomegalovirus UL128 complex induces 624 broadly neutralizing antibodies in rhesus macaques

Multiantigenic Modified Vaccinia Virus Ankara Vaccine Vectors To Elicit 627

Potent Humoral and Cellular Immune Reponses against Human Cytomegalovirus in Mice

MVA vaccine encoding CMV antigens safely induces durable expansion of CMV-630 specific T-cells in healthy adults

Poxvirus Vectored Cytomegalovirus Vaccine to Prevent Cytomegalovirus Viremia 632 in Transplant Recipients: A Phase 2, Randomized Clinical Trial

Complete regression of cutaneous metastases with systemic immune response in 635 a patient with triple negative breast cancer receiving p53MVA vaccine with pembrolizumab. 636 Oncoimmunology 6, e1363138

Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in 638 hamsters

A single-dose live-attenuated YF17D-vectored SARS-CoV-2 vaccine 640 candidate

A single dose of recombinant VSV-G-spike vaccine provides protection 642 against SARS-CoV-2 challenge

Simulation of the Clinical and Pathological Manifestations of Coronavirus 644 Disease 2019 (COVID-19) in a Golden Syrian Hamster Model: Implications for Disease 645

Pathogenesis and transmission of SARS-CoV-2 in golden hamsters

Syrian hamsters as a small animal model for SARS-CoV-2 infection and 649 countermeasure development

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a 652

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Establishment of an African green monkey model for COVID-19 and protection 659 against re-infection

Respiratory disease in rhesus macaques inoculated with SARS-CoV-2. 661

SARS-CoV-2 infection protects against rechallenge in rhesus macaques

Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman 665 Primates

BNT162b vaccines protect rhesus macaques from SARS-CoV-2

ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus 669 macaques

DNA vaccine protection against SARS-CoV-2 in rhesus macaques

Intranasal exposure of African green monkeys to SARS-CoV-2 results in acute 673 phase pneumonia with shedding and lung injury still present in the early convalescence phase

SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses 676 in COVID-19 convalescent donors and vaccinees

A modified vaccinia Ankara vector-based vaccine protects macaques from 679 SARS-CoV-2 infection, immune pathology, and dysfunction in the lungs

One or two injections of MVA-vectored vaccine shields hACE2 transgenic mice from 682 SARS-CoV-2 upper and lower respiratory tract infection

COVID-19 vaccine candidates based on modified vaccinia virus Ankara 685 expressing the SARS-CoV-2 spike induce robust T-and B-cell immune responses and full efficacy 686 in mice

Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-688

SARS-2-S in preclinical vaccination

Intranasal plus subcutaneous prime vaccination with a dual antigen COVID-19 691 vaccine elicits T-cell and antibody responses in mice

The potential danger of suboptimal antibody responses in COVID-19

Rapid COVID-19 vaccine development

Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine 698 candidate for Middle East respiratory syndrome: an open-label, phase 1 trial

An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV 701 infection in dromedary camels

Induced bronchus-associated lymphoid tissue serves as a general priming site for 703 T cells and is maintained by dendritic cells

Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-706

CoV-2 Spike Protein for Neutralization Assays

We would like to thank Angela Wong and Christina Ulloa for helping with laboratory logistics and 710 secretarial support. We would like to acknowledge the Bioqual team for their technical support

We gratefully acknowledge City of Hope's unique internal funding mechanism of selected 712 scientific discoveries, enabling preclinical and clinical development to speedily advance products 713 toward commercialization, such as COH04S1. The following reagent was

NR-53780. Don J. Diamond was partially 716 supported by the following Public Health Service grants: U19 AI128913, CA111412, CA181045, 717 and CA107399. The content is solely the responsibility of the authors and does not necessarily 718 represent the official views of the National Institutes of Health

Values 764 below the limit of detection (PRNT=20) are indicated as 10. One-way ANOVA with Holm-Sidak's 765 multiple comparison test was used. h. VOC-specific NAb titers. NAb were measured in pooled 766 serum samples of vaccine and control groups collected at the time of challenge (d42) using 767 pseudovirus (pv) variants with S D614G mutation or S modifications based on several VOC, 768 including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), and Delta (B.1.617.2). Titers are 769 expressed as NT50

Tukey's multiple comparison test was used

Panel h shows representative 796 images of histopathological findings in lung sections of COH04S1-vaccinated animals and control 797 animals. Black arrows indicate moderate and mild bronchioalveolar hyperplasia in lung sections 798 of sMVA-IM and sMVA-IN control animals as well as COH04S1-IN animals. Black arrows in lung 799 sections of unvaccinated control animals indicate hyperplastic alveolar cells. 10x magnification. 800 were measured by ELISA at day 42 in BAL samples of COH04S1-IM and COH04S1-IN vaccine 819 group. Endpoint titers are presented as geometric mean values ± geometric SD. Two-way ANOVA 820 with Sidak's multiple comparison test was used. g. NAb titers

Two-way ANOVA followed by Sidak's multiple comparison test was 824 used to compare ID50 values. PRNT-assayed NAb titers measured in serum samples of 825 healthcare workers (N=14) vaccinated two times with Pfizer-BioNTech BNT162b2 mRNA vaccine 826 were included. h-i. T cell responses. IFNγ, IL-2, and IL-4-expressing S and N-antigen-specific T 827 cell responses were measured at day 42 by ELISPOT. Bars represent mean values, lines 828 represent ±SD. Two-way ANOVA followed by Tukey's multiple comparison test was used

Time-points with <3 samples/group (d+15 and d+21) were excluded from the statistical 868 evaluation

Funds were allocated to Don J. Diamond by the City of Hope (COH) for research that resulted in 728 the development of COH04S1, the multi-antigenic SARS-CoV-2 vaccine using a synthetic 729 poxvirus platform that is discussed in this publication. While unknown whether publication of this 730 report will aid in receiving grants and contracts, it is possible that this publication will be of benefit 731 to COH. COH had no role in the conceptualization, design, data collection, analysis, decision to 732 publish, or preparation of the manuscript. COH submitted two PCT applications. Don J. Diamond 733 is a co-inventor on two patent applications that were submitted by COH to the USPTO. values ± geometric SD. Two-way ANOVA with Sidak's multiple comparison test was used for 817statistical analysis. f. BAL antibody titers. S, RBD, and N antigen-specific binding antibody titers 818